Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 3/20 | 0.53 |
| ▸ | SMPD3 | Q9NY59 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | STS | P08842 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.42 |
| ▸ | PDE4A | P27815 | 1/20 | 0.42 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4210773 | 0.86 | ADRA1A (0.58) | ADRA1AALDH1A1DRD2DRD3LMNA | |
| SCHEMBL4222227 | 0.84 | GPR119 (0.45) | ALDH1A1GPR119LMNAMAPT | |
| SCHEMBL14591361 | 0.82 | KDM1A (0.47) | ALDH1A1GPR119LMNAMAPT | |
| SCHEMBL14591362 | 0.82 | KDM1A (0.47) | ALDH1A1GPR119LMNAMAPT | |
| SCHEMBL4221097 | 0.81 | ALDH1A1 (0.44) | SMPD3ALDH1A1STSTP53PDE4B | |
| SCHEMBL4212633 | 0.80 | ADRA1A (0.66) | ADRA1ADRD2DRD3 | |
| SCHEMBL20722901 | 0.76 | DPP4 (0.45) | TP53GPR119LMNAMAPT | |
| SCHEMBL30061913 | 0.76 | DPP4 (0.45) | TP53GPR119LMNAMAPT | |
| SCHEMBL7246642 | 0.75 | ADRA1A (0.66) | ADRA1ADRD2DRD3 | |
| SCHEMBL6819833 | 0.75 | ADRA1A (0.66) | ADRA1ADRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090054453-A1 | Novel Tetralins as 5-HT6 Modulators | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054453-A1 | Novel Tetralins as 5-HT6 Modulators | HTR6, TPH1, HTR1A | ADRA1A 75/4885SMPD3 2949/4885ALDH1A1 3256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.